Capsule Summary Slidesets

Share

Program Content

Activities

  • KEYNOTE-177 Final Analysis
    KEYNOTE-177 Final Analysis: First-line Pembrolizumab vs Chemotherapy in MSI-H/dMMR Metastatic CRC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 17, 2021

    Expires: June 16, 2022

  • CheckMate 649: Nivo + CT for GEC
    CheckMate 649: Additional Analysis From the Phase III Trial of First-line Nivolumab + CT vs CT for Advanced Gastroesophageal Cancers
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2021

    Expires: June 09, 2022

  • CheckMate 577 Update
    CheckMate 577 Update: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 17, 2021

    Expires: June 16, 2022

  • KEYNOTE-811
    KEYNOTE-811: First-line Pembrolizumab + Trastuzumab and Chemotherapy in HER2+ Metastatic Gastric or Gastroesophageal Junction Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 17, 2021

    Expires: June 16, 2022

  • CheckMate 648
    CheckMate 648: Nivolumab + Ipilimumab or Chemotherapy vs Chemotherapy Alone for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

Provided by

ProCE Banner

Supporters

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme